In advanced NSCLC patients with sensitizing EGFR mutations, EGFR-TKIs have been found to effectively improve clinical outcomes, relative to cytotoxic chemotherapies (2–5). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.